Aflibercept Intervention in Experimental Branch Retinal Vein Occlusion Results in Upregulation of DnaJ Homolog Subfamily C Member 17

Aflibercept Intervention in Experimental Branch Retinal Vein Occlusion Results in Upregulation of DnaJ Homolog Subfamily C Member 17

Aflibercept is an inhibitor of vascular endothelial growth factor (VEGF) used to treat macular edema following branch retinal vein occlusion (BRVO). Despite well-documented efficacy, there is limited knowledge about proteome changes following aflibercept intervention in BRVO. Proteome changes may pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Lasse Jørgensen Cehofski, Anders Kruse, Alexander Nørgård Alsing, Benn Falch Sejergaard, Jonas Ellegaard Nielsen, Shona Pedersen, Danson Vasanthan Muttuvelu, Svend Kirkeby, Bent Honoré, Henrik Vorum
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2021/6690260
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1155/2021/6690260

Similar Items